A 59-year-old with recurrent CDI received fidaxomicin. To reduce recurrence, which adjunct may be considered in high-risk patients during antibiotic t...

Question

A 59-year-old with recurrent CDI received fidaxomicin. To reduce recurrence, which adjunct may be considered in high-risk patients during antibiotic therapy?

Accepted Answer

Bezlotoxumab infusion

Answer

Probiotics only

Answer

Repeat metronidazole

Answer

No adjuncts available

Answer

Loperamide

us-abim MCQ (SBA): CDI-Recurrence Prevention

A 59-year-old with recurrent CDI received fidaxomicin. To reduce recurrence, which adjunct may be considered in high-risk patients during antibiotic therapy?